Bonding Matters

From our scientific platform to our collaborative culture to our patient engagement, bonding is at the core of our efforts to transform the treatment of immune-mediated diseases. Learn more

Bonding Matters

From our scientific platform to our collaborative culture to our patient engagement, bonding is at the core of our efforts to transform the treatment of immune-mediated diseases. Learn more
Technology

Precision Bonding with Tailored Covalency

Our proprietary scientific platform differentiates our drug candidates from conventional small molecules.
Technology
Pipeline

Multiple Clinical-Stage Programs

Our portfolio features highly selective, novel drug candidates for underserved immune-mediated diseases.

Recent News

Principia is now a Sanofi company.

As of September 28, 2020, Sanofi and Principia have joined forces to expand and accelerate the potential benefits of therapies for patients with immune-mediated diseases. We will work together to bring these novel therapies to patients faster. Read press release.

Enter Website